| ABIVAX SA EO -,01 |
| Frankreich |
| Gesundheit |
| FR0012333284 / A14UQC |
| 2X1 (Frankfurt) |
| FRA:2X1, ETR:2X1, 2X1:GR |
| - |
| https://www.abivax.com/ |
|
Abivax SA is a clinical-stage biotechnology company that develops therapeutics designed to harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Headquartered in Paris, Fra..
>Volltext.. |
| 8594.03 Mio. EUR |
| 8136.48 Mio. EUR |
| - |
| -258.1 Mio. EUR |
| -331.26 Mio. EUR |
| -4.51 EUR |
| 34.11 Mio. EUR |
| 476.07 Mio. EUR |
| -177.34 Mio. EUR |
| 7.9 |
| - |
| -124.85% |
| - |
| - |
| - |
| - |
| ABIVAX |
| 04.09.26 |
|
||||
|
||||
|